Invention Grant
- Patent Title: 2,3-benzodiazepines
-
Application No.: US14421994Application Date: 2013-08-13
-
Publication No.: US09890147B2Publication Date: 2018-02-13
- Inventor: Stephan Siegel , Stefan Bäurle , Arwed Cleve , Bernard Haendler , Amaury Ernesto Fernandez-Montalvan , Ursula Mönning , Sabine Krause , Pascale Lejeune , Norbert Schmees , Matthias Busemann , Simon Holton , Joachim Kuhnke
- Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
- Applicant Address: DE Berlin
- Assignee: Bayer Pharma Aktiengesellshaft
- Current Assignee: Bayer Pharma Aktiengesellshaft
- Current Assignee Address: DE Berlin
- Priority: DE102012214602 20120816; DE102013202104 20130208
- International Application: PCT/EP2013/066931 WO 20130813
- International Announcement: WO2014/026997 WO 20140220
- Main IPC: A61K31/551
- IPC: A61K31/551 ; C07D243/02 ; C07D401/04 ; C07D403/04 ; C07D417/10 ; C07D401/14 ; C07D413/14 ; C07D401/10 ; C07D401/12 ; C07D403/10 ; C07D403/14 ; C07D409/10 ; C07D413/04 ; C07D413/10 ; A61K31/5513

Abstract:
What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumor disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.
Public/Granted literature
- US20150203483A1 2,3-BENZODIAZEPINES Public/Granted day:2015-07-23
Information query